Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 5Active not recruiting 3Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Leukemia 1Glioblastoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Specimen Handling 482pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 241Paclitaxel 226Gemcitabine 224Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 166Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 143Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Valacyclovir × 1 year × Clear all
NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
11 enrolled
CNS

Brain Neoplasms

NCT07346144 2026-05-04

ADePT

Trogenix ltd

Phase 1/2 Recruiting
68 enrolled
CNS

Glioblastoma

NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07294547 2025-12-19

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

National Taiwan University Hospital

Phase NA Recruiting
80 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡